SuperQuick® Cytochrome P450 2C19 (CYP2C19) Activity Assay Kit

DMK-YS007

The oxidation of neutral or slightly basic lipophilic compounds with 2-3 hydrogen bound donor/acceptor sites is catalyzed by CYP2C19, which is primarily expressed in the liver and intestinal organs. CYP2C19 subfamily isoforms play a role in the metabolism of roughly 20% of routinely prescribed small molecule medicines. Clinical drug-drug interactions involving a wide range of prescribed drugs, including proton pump inhibitors, antiplatelet agents, and anticonvulsants, have been linked to the human CYP2C19 gene polymorphisms. Furthermore, CYP2C19 inhibition or allelic impairment can diminish therapeutic efficacy for medicines whose pharmacological activity requires metabolism from the prodrug form.CYP2C19 inhibition or allelic deficiency can lead to reduced drug efficacy.Creative Bioarray's CYP2C19 Activity Assay Kits enable rapid measurement of native or recombinant CYP2C19 activity in biological samples, such as liver microsomes.

Rapid assessment of native/recombinant CYP2C19 activity in fractions prepared from tissues and cells.
Screening compounds for interaction with native/recombinant CYP2C19.

Simple and ready to use;
With little interference by autofluorescence.
Rapid and hight sensitive.

Liver microsomes and liver S9 fractions;
Tissue and cultured cell lysates, primary hepatocytes;
Heterologous expression of recombinant CYP2C19 preparations.

CYP2C19 Assay Buffer;
3-CHC Standard;
CYP2C19Inhibitor ((+)-N-3-benzylnirvanol);
NADPH Generating System(100X);
β-NADP+Stock (100X);
CYP2C19 Substrate;
Recombinant Human CYP2C19.

100 assys

Strore at -20℃.

Gel Pack

If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.